Compositions and method for detecting human parvovirus nucleic acid and for detecting hepatitis a virus nucleic acids in single-plex or multiplex assays

Abstract

Nucleic acid oligomers specific for human parvovirus genomic DNA. An assay for amplifying and detecting human parvovirus genotypes 1, 2 and 3 nucleic acid in biological specimens. Compositions for amplifying and detecting the presence of human parvovirus genotypes 1, 2 and 3 genomic DNA in human biological specimens.

1 - 20 . (canceled) 
     
     
         21 . An oligomer combination for detecting a human parvovirus target nucleic acid and a hepatitis A virus (HAV) target nucleic acid in a sample, said oligomer combination comprising:
 (I) first and second amplification oligomers for amplifying a human parvovirus nucleic acid target region, wherein
 (a) the first parvovirus amplification oligomer comprises a first target-hybridizing sequence that is from 14 to 27 contiguous nucleotides contained in the sequence of SEQ ID NO: 181 and that includes at least the sequence of SEQ ID NO: 117, SEQ ID NO: 179 or SEQ ID NO: 180; and 
 (b) the second parvovirus amplification oligomer comprises a second target-hybridizing sequence selected from the group consisting of:
 (i) a sequence that is from 14 to 30 contiguous nucleotides contained in the sequence of SEQ ID NO: 189 and that includes at least the sequence of SEQ ID NO: 188; and 
 (ii) a sequence that is from 14 to 30 contiguous nucleotides contained in the sequence of SEQ ID NO: 193 and that includes at least the sequence of SEQ ID NO: 192; and 
 
   (II) first and second amplification oligomers for amplifying an HAV nucleic acid target region, wherein
 (a) the first HAV amplification oligomer comprises a first target-hybridizing sequence that is from 14 to 27 contiguous nucleotides contained in the sequence of SEQ ID NO: 174 and that includes at least the sequence of SEQ ID NO: 173; and 
 (b) the second HAV amplification oligomer comprises a second target-hybridizing sequence that is from 14 to 30 contiguous nucleotides contained in the sequence of SEQ ID NO: 177 and that includes at least the sequence of SEQ ID NO: 175. 
   
     
     
         22 . The oligomer combination of  claim 21 , wherein the first parvovirus target-hybridizing sequence of said (I)(a) is contained in the sequence of SEQ ID NO: 182 and includes at least the sequence of SEQ ID NO: 179 
     
     
         23 . The oligomer combination of  claim 21 , wherein the first parvovirus target-hybridizing sequence of said (I)(a) is contained in the sequence of SEQ ID NO: 184 
     
     
         24 . The oligomer combination of  claim 21 , wherein the first parvovirus target-hybridizing sequence of said (I)(a) is contained in the sequence of SEQ ID NO: 185 and includes at least the sequence of SEQ ID NO: 180 
     
     
         25 . The oligomer combination of  claim 21 , wherein the second parvovirus target-hybridizing sequence of said (I)(b) is contained in the sequence of SEQ ID NO: 187 and includes at least the sequence of SEQ ID NO: 188 
     
     
         26 . The oligomer combination of  claim 21 , wherein the second parvovirus target-hybridizing sequence of said (I)(b) is contained in the sequence of SEQ ID NO: 191 
     
     
         27 . The oligomer combination of  claim 22 , wherein the first parvovirus target-hybridizing sequence of said (I)(a) includes a sequence selected from the group consisting of SEQ ID NOs: 75-80, SEQ ID NO: 117, and SEQ ID NO: 183. 
     
     
         28 . The oligomer combination of  claim 23 , wherein the first parvovirus target-hybridizing sequence of said (I)(a) is selected from the group consisting of SEQ ID NOs: 81-84. 
     
     
         29 . The oligomer combination of  claim 24 , wherein the first parvovirus target-hybridizing sequence of said (I)(a) is selected from the group consisting of SEQ ID NOs: 82-84. 
     
     
         30 . The oligomer combination of  claim 25 , wherein the second parvovirus target-hybridizing sequence of said (I)(b) includes a sequence selected from the group consisting of SEQ ID NOs: 108-113 and SEQ ID NO: 186. 
     
     
         31 . The oligomer combination of  claim 26 , wherein the second parvovirus target-hybridizing sequence of (I)(b) includes a sequence selected from the group consisting of SEQ ID NOs: 118-121 and SEQ ID NO: 190. 
     
     
         32 . The oligomer combination of  claim 21 , further comprising:
 (III) third and fourth amplification oligomers for amplifying the human parvovirus nucleic acid target region, wherein
 (a) the third parvovirus amplification oligomer comprises a third target-hybridizing sequence that is from 14 to 27 contiguous nucleotides contained in the sequence of SEQ ID NO: 181 and that includes at least the sequence of SEQ ID NO: 117, SEQ ID NO: 179 or SEQ ID NO: 180; and 
 (b) the fourth parvovirus amplification oligomer comprises a fourth target-hybridizing sequence selected from the group consisting of:
 (i) a sequence that is from 14 to 30 contiguous nucleotides contained in the sequence of SEQ ID NO: 189 and that includes at least the sequence of SEQ ID NO: 188; and 
 (ii) a sequence that is from 14 to 30 contiguous nucleotides contained in the sequence of SEQ ID NO: 193 and that includes at least the sequence of SEQ ID NO: 192, 
 
   wherein the third target-hybridizing sequence of said (III)(a) is different from the first parvovirus target-hybridizing sequence of said (I)(a); and   wherein the fourth target-hybridizing sequence of said (III)(b) is different from the second parvovirus target-hybridizing sequence of said (I)(b).   
     
     
         33 . The oligomer combination of  claim 21 , further comprising:
 (IV) third and fourth amplification oligomers for amplifying the HAV nucleic acid target region, wherein
 (a) the third HAV amplification oligomer comprises a third target-hybridizing sequence that is from 14 to 27 contiguous nucleotides contained in the sequence of SEQ ID NO: 174 and that includes at least the sequence of SEQ ID NO: 173; and 
 (b) the fourth HAV amplification oligomer comprises a fourth target-hybridizing sequence that is from 14 to 30 contiguous nucleotides contained in the sequence of SEQ ID NO: 177 and that includes at least the sequence of SEQ ID NO: 175;
 wherein the third target-hybridizing sequence of said (IV)(a) is different from the first HAV target-hybridizing sequence of said (II)(a); and 
 wherein the fourth target-hybridizing sequence of said (IV)(b) is different from the second HAV target-hybridizing sequence of said (II)(b). 
 
   
     
     
         34 . A kit comprising the oligomer combination of  claim 21 . 
     
     
         35 . A reaction mixture comprising the oligomer combination of  claim 21 . 
     
     
         36 . A method for detecting a human parvovirus target nucleic acid and a hepatitis A virus (HAV) target nucleic acid in a sample, said method comprising:
 (A) in a sample suspected of containing human parvovirus and HAV, contacting said sample with the oligomer combination according to  claim 21  or the kit according to  claim 29  or the reaction mixture according to  claim 30 ;   (B) performing an in vitro nucleic acid amplification reaction, wherein any parvovirus and/or HAV target nucleic acid present in said sample is used as a template for generating a parvovirus and/or HAV amplification product; and   (C) detecting the presence or absence of the parvovirus and/or HAV amplification product, thereby indicating the presence or absence of parvovirus and/or HAV in said sample.   
     
     
         37 . The method of  claim 36 , wherein the detection of the human parvovirus target nucleic acid and the hepatitis A virus (HAV) target nucleic acid is conducted in an in vitro sample.